Autifony Therapeutics — Updated FAQs

Q. What is the QUIET-1 study?

Q. What is AUT00063?

Q. Can I have some details of the drug itself, and how will it be administered during the trial?

Q. What are the side effects of AUT00063?

Q. How do I know whether or not I am eligible to take part in the QUIET-1 study?

Q. Who should I contact to find out more about enrolment in the QUIET-1 study?

Q. What age restrictions apply to the study?

Q. Can I enter the study with normal hearing or do you have to have hearing loss to get a benefit from “063”? Are there plans to remove this requirement?

Q. Can a subject with hearing loss in only 1 ear still take part?

Q. Will this drug adversely affect my hearing?

Q. Can subjects with Chronic, i.e. longer term, tinnitus participate?

Q. How soon does the drug start to work?

Q. Why are some sites doing EEG (ElectroEncephaloGraphy) and what is this for?

Q. If I also suffer from hearing loss, can I expect to see an improvement in my audiogram, as I know AUT00063 is being tested also for Age Related Hearing Loss in the USA?

Q. Are non-UK residents able to participate?

Q. When is a tinnitus study coming to the USA?

Q. If I cannot participate, will Autifony suggest possible treatment or therapy?

Q. If the study is successful then what would be the estimated arrival time to market?

Q. Do you expect “063” to work for all types of tinnitus or is the focus on specific sub-types?

Q. How similar is “063” to other potassium channel drugs (such as Retigabine)?

Q. Is the dosage fixed or do you expect to see benefits from increasing it in some cases?

Q. Is “063” to be taken for the 30 days only or is it something that will need to be taken indefinitely?